Impact of HLA-G polymorphism on the outcome of allogeneic hematopoietic stem cell transplantation for metastatic renal cell carcinoma

Crocchiolo, Roberto; Ringdén, Olle; Jo, Bay; Blaise, Didier; Omasic, B; Mazzi, Benedetta; Picard, Christophe; Trinca, Stefania; Barkholt, Lisbeth; Peccatori, Jacopo; Gregori, Silvia; Amodio, Giada; Fleischhauer, Katharina; Ciceri, Fabio; Bregni, Marco

doi:10.1038/bmt.2017.243

Cited by 7 publications

(7 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the context of allogeneic hematopoietic stem cell transplantation (HSCT), it has been shown that patients with better outcome carried 14-bp DEL/DEL and 14-bp INS/DEL genotypes, suggesting 14-bp INS/DEL genotype as potential biomarker of transplantation outcome (32,33). Overall, the association between 14-bp INS/DEL genotypes and disease susceptibility provided some positive, but not conclusive, association.…”

Section: Hla-g Genetic Footprint and Correlation With Disease Coursementioning

confidence: 99%

HLA-G Genotype/Expression/Disease Association Studies: Success, Hurdles, and Perspectives

Amodio

Gregori

2020

Front. Immunol.

View full text Add to dashboard Cite

The non-classical HLA-G is a well-known immune-modulatory molecule. In physiological condition, HLA-G surface expression is restricted to the maternal-fetal interface and to immune-privileged adult tissues, whereas soluble forms of HLA-G are detectable in various body fluids. HLA-G can be de novo expressed in pathological conditions including tumors, chronic infections, or after allogeneic transplantation. HLA-G exerts positive effects modulating innate and adaptive immune responses and promoting tolerance, or detrimental effects inducing immune escape mechanisms. HLA-G locus, in contrast to classical HLA class I gene, is highly polymorphic in the non-coding 3 ′ untranslated region (UTR) and in the 5 ′ upstream regulatory region (5 ′ URR). Variability in these regions influences HLA-G expression by modifying mRNA stability or allowing posttranscriptional regulation in the case of 3 ′ UTR or by sensing the microenvironment and responding to specific stimuli in the case of HLA-G promoter regions (5 ′ URR). The influence of genetic variations on the expression of HLA-G makes it an attractive biomarker to monitor disease predisposition and progression, or response to therapy. Here, we summarize the current knowledge, efforts, and obstacles to generate a general consensus on the correlation between HLA-G genetic variability, protein expression, and disease predisposition. Moreover, we discuss perspectives for future investigation on HLA-G genotype/expression in association with disease predisposition and progression.

show abstract

Section: Hla-g Genetic Footprint and Correlation With Disease Coursementioning

confidence: 99%

HLA-G Genotype/Expression/Disease Association Studies: Success, Hurdles, and Perspectives

Amodio

Gregori

2020

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…However, no concordant results could be observed regarding pregnancy loss, autoimmune diseases or cancer (Jiang et al., 2019; Kim et al., 2015; Li et al., 2015; Monti et al., 2019). As for the impact of HLA‐G in haematopoietic stem cell transplantation, 14 bp INS/DEL and 14 bp DEL/DEL haplotypes were reported to be transplantation markers for better outcomes (Chiusolo et al., 2012; Crocchiolo et al., 2018).…”

Section: Nonclassical Hla Moleculesmentioning

confidence: 99%

Extended loci histocompatibility matching in HSCT—Going beyond classical HLA

Neuchel

Fürst

Tsamadou

et al. 2021

Int J Immunogenetics

View full text Add to dashboard Cite

Unrelated haematopoietic stem cell transplantation (HSCT) has evolved from an experimental protocol to a potentially curative first‐line treatment in a variety of haematologic malignancies. The continuous refinement of treatment protocols and supportive care paired with ongoing achievements in the technological field of histocompatibility testing enabled this transformation. Without a doubt, HLA matching is still the foremost criterion for donor selection in unrelated HSCT. However, HSCT‐related treatment complications still occur frequently, often resulting in patients suffering severely or even dying as a consequence of such complications. Current literature indicates that other immune system modulating factors may play a role in the setting of HSCT. In this review, we discuss the current clinical evidence of a possible influence of nonclassical HLA antigens HLA‐E, HLA‐F, and HLA‐G as well as the HLA‐like molecules MICA and MICB, in HSCT.

show abstract

“…There are studies showing the impact of genotyping and matching for non-classical HLA (including HLA-E, HLA-G or MICA/B loci) on HSCT outcome, including manifestation of cGvHD (reviewed in ( 46 , 59 , 60 ), and the role of anti-MICA antibodies in organ transplant recipients. Therefore, non-classical HLA molecules should also be considered as potential targets of alloantibodies in HSCT recipients.…”

Section: Alloantibodies and Gvhdmentioning

confidence: 99%

Potential Novel Biomarkers in Chronic Graft-Versus-Host Disease

et al. 2020

View full text Add to dashboard Cite

Prognostic, diagnostic or predictive biomarkers are urgently needed for assessment of chronic graft-versus-host disease (cGvHD), a major risk for patients undergoing allogeneic hematopoietic stem cell transplantation. The main goal of this review generated within the COST Action EUROGRAFT “Integrated European Network on Chronic Graft Versus Host Disease” was to identify potential novel biomarkers for cGvHD besides the widely accepted molecular and cellular biomarkers. Thus, the focus was on cellular biomarkers, alloantibodies, glycomics, endothelial derived particles, extracellular vesicles, microbiome, epigenetic and neurologic changes in cGvHD patients. Both host-reactive antibodies in general, and particularly alloantibodies have been associated with cGvHD and require further consideration. Glycans attached to IgG modulate its activity and represent a promising predictive and/or stratification biomarker for cGVHD. Furthermore, epigenetic changes such as microRNAs and DNA methylation represent potential biomarkers for monitoring cGvHD patients and novel targets for developing new treatment approaches. Finally, the microbiome likely affects the pathophysiology of cGvHD; bacterial strains as well as microbial metabolites could display potential biomarkers for dysbiosis and risk for the development of cGvHD. In summary, although there are no validated biomarkers currently available for clinical use to better inform on the diagnosis, prognosis or prediction of outcome for cGvHD, many novel sources of potential markers have shown promise and warrant further investigation using well characterized, multi-center patient cohorts.

show abstract

Impact of HLA-G polymorphism on the outcome of allogeneic hematopoietic stem cell transplantation for metastatic renal cell carcinoma

Cited by 7 publications

References 37 publications

HLA-G Genotype/Expression/Disease Association Studies: Success, Hurdles, and Perspectives

HLA-G Genotype/Expression/Disease Association Studies: Success, Hurdles, and Perspectives

Extended loci histocompatibility matching in HSCT—Going beyond classical HLA

Potential Novel Biomarkers in Chronic Graft-Versus-Host Disease

Contact Info

Product

Resources

About